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ABSTRACT
Introduction: Injectable therapies such as glu-
cagon-like peptide-1 receptor agonists (GLP-1
RAs) and basal insulin (BI) are well-established
agents for people with type 2 diabetes (T2D).
This study aimed to investigate real-world
effectiveness of GLP-1 RAs or BI in adults with
T2D poorly controlled on oral antihyper-
glycemic drugs (OADs).
Methods: This was a retrospective, observa-
tional, longitudinal cohort study of adults with
T2D from the US Optum Humedica database
and UK Clinical Practice Research Datalink, who
initiated either injectable between January 1,
2010, and June 30, 2016. Baseline characteris-
tics, glycated hemoglobin (HbA1c) change, and
cumulative percentage reaching HbA1c\ 7% in
24 months after initiation were analyzed in four
patient cohorts.
Results: In the US and UK databases, respec-
tively, 20,836 and 5508 patients initiated GLP-1
RAs and 60,598 and 5083 initiated BI. Baseline
mean HbA1c at initiation ranged between 8.8%
and 10.3% across all cohorts. In all cohorts, a
decrease of HbA1c occurred 3–6 months after
initiation. The cumulative percentage of
patients reaching HbA1c\7% showed the
greatest probability in the first 12 months
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(15–40% of patients across cohorts at
12 months), particularly in the first 6 months
after initiation. The probability of reaching
glycemic control diminished after the second
quarter. The proportion of patients reaching
HbA1c\ 7% in both GLP-1 RA and BI cohorts at
12 months was\25% if baseline HbA1c
was C 9%.
Conclusions: For adults with T2D inadequately
controlled on OADs, this analysis reveals an unmet
clinical need. Initiation of first injectable therapy
did not occur until HbA1c was considerably above
target, when control is harder to achieve. Results
suggest that in individuals with baseline HbA1c
C 9.0%, only a minority are likely to achieve an
HbA1c\7% with a GLP-1 RA or BI alone.
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Key Summary Points
Why carry out this study?
Injectable therapies such as glucagon-like
peptide-1 receptor agonists (GLP-1 RAs)
and basal insulin (BI) are well-established
agents for people with type 2 diabetes
(T2D) with demonstrated
antihyperglycemic efficacy in randomized
controlled trials.
This study was conducted to investigate
the effectiveness of initiating therapy with
either GLP-1 RA or BI in real-world clinical
practice.
What was learned from the study?
Initiation of BI or GLP-1 RA was often
delayed until the patient had reached
high HbA1c values (between 8.8% and
10.3% in this study).
People on oral antihyperglycemic drugs
with glycated hemoglobin (HbA1c)
C 9.0% generally were unlikely to achieve
control with GLP-1 RA or BI alone.
If patients had not achieved control
within 6–12 months of initiating BI or
GLP-1 RA, the probability of reaching
control without a treatment change was
low
Treatment intensification should be
considered if people are not well
controlled after 6–12 months on either
injectable.
INTRODUCTION
The benefits of achieving glycemic control
(glycated hemoglobin [HbA1c]\7%) to reduce
the risk of complications for people with type 2
diabetes (T2D) are well established [1, 2]. Most
people with T2D require pharmacological
intervention alongside lifestyle modification
with medical nutrition therapy and appropri-
ately prescribed physical activity to attain and
maintain glycemic targets [3]. Pharmacologic
intervention is usually initiated with a single
oral agent followed by sequential addition of
oral agents before intensification to
injectables [1–3].
Injectable therapies such as glucagon-like
peptide-1 receptor agonists (GLP-1 RAs) and
basal insulin (BI) are well-established agents for
people with T2D with demonstrated antihy-
perglycemic efficacy in randomized clinical tri-
als (RCTs) [4, 5]. Reported ranges of people
achieving HbA1c\ 7% after initiation are
46–63% for GLP-1 RAs or 39–70% for BI [6–8].
However, there are concerns about generalizing
RCT evidence of efficacy to effectiveness in
routine clinical practice. In the environment of
an RCT, participants are highly motivated and
selected through many eligibility criteria [9] and
closely followed up and monitored. In routine
clinical care, the population treated for T2D is
much broader, treatment may be initiated later
[10, 11], adherence to therapy is variable [9],
and interactions between healthcare profes-
sionals (HCPs) and patients may be less frequent
and comprehensive than in RCTs. For example,
differences between RCT and clinical practice
patient populations were demonstrated in a
real-world study of Danish adults receiving the
GLP-1 RA liraglutide, in which only approxi-
mately one in four participants would have
been eligible for inclusion in the LEAD RCTs
[12]. Furthermore, some subpopulations are
often underrepresented in RCTs, such as
those[65 years of age, with more comorbidi-
ties and/or concomitant medications, and from
lower socioeconomic backgrounds [13]. The
need for real-world evidence of effectiveness
and safety of medications to complement the
RCT evidence has increased, along with requests
from multiple stakeholders including HCPs,
health systems, payers, regulators, and industry
[14].
The current study was conducted to investi-
gate the effectiveness of initiating therapy with
either a GLP-1 RA or BI in real-world clinical
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practice in people with T2D inadequately con-
trolled on oral antihyperglycemic drugs (OADs)
by analyzing the electronic medical records
(EMR) and claims data from the US Optum
Humedica and UK Clinical Practice Research
Datalink (CPRD) databases and to evaluate fac-
tors that might predict treatment success.
MATERIALS AND METHODS
Study Design
This was a retrospective, observational, longi-
tudinal cohort study of US or UK adults with
T2D who initiated a GLP-1 RA or BI between
January 1, 2010 and June 30, 2016 and were
followed up for 2 years up to June 30, 2018
(Figure S1). Data were taken from the US Optum
Humedica [15] and UK CPRD [16] databases.
The Optum Humedica database is a large,
representative, real-world EMR and claims
database in the US, holding data for[90 mil-
lion people from multiple academic and com-
munity integrated delivery networks, including
hospitals, emergency departments, and ambu-
latory care settings.
The UK CPRD database is a large, real-world
research service supporting retrospective and
prospective health and clinical studies. It is
sponsored by the Medicines and Healthcare
Products Regulatory Agency and the National
Institute for Health Research as part of the
Department of Health and Social Care. The
database collects anonymized longitudinal
patient data from a network of general practi-
tioner practices across the UK; data are repre-
sentative of the UK population with respect to
demographic factors. These data encom-
pass[42 million patient lives, including 13
million currently registered patients.
Ethics committee approval was not required
as this was a retrospective observational study of
existing anonymized electronic medical record
data that were collected in daily clinical prac-
tice. No intervention was implemented on the
patients for the purpose of the study, and no
patient-identifiable information was used in the
study.
Study Population
Patients were included in this analysis if they
had diagnosis of T2D or unspecified diabetes at
any time; initiated GLP-1 RA or BI within the
identification period of January 1, 2010, to June
30, 2016; were C 18 years of age on the index
date (date of first prescription of either inject-
able); had C 180 days of recorded medical his-
tory before and 720 days after the index date;
were taking C 1 OAD during the 180-day base-
line period; had most recent HbA1c C 7%
within 90 days before and 14 days after the
index date; and had C 1 valid HbA1c record
within 15 and 720 days after GLP-1 RA or BI
initiation (Table S1). The GLP-1 RAs included
exenatide, liraglutide, lixisenatide, albiglutide,
or dulaglutide. The BIs included neutral pro-
tamine Hagedorn insulin, insulin detemir,
insulin glargine 300 U/ml (Gla-300), and insulin
glargine 100 U/ml (Gla-100) or degludec (U-100
and U-200).
Patients were excluded from the study if they
had a diagnosis of type 1 diabetes (T1D) at any
time, gestational diabetes within 180 days
before the index date, or polycystic ovary syn-
drome at any time before the index date.
Comorbidities and diagnosis of any exclu-
sion criteria (T1D, gestational diabetes, or
polycystic ovary syndrome) were identified
from patient records using diagnostic codes.
Persistence of BI or GLP-1 RA Use
Persistence was defined as having repeated pre-
scriptions for the index injectable (BI or GLP-1
RA) within an estimated refill period, estimated
as the 95th percentile of the number of days
between subsequent prescriptions (second up to
fifth consecutive prescriptions for patients
with C 5 prescriptions). Date of discontinua-
tion was defined as the date of final prescription
plus an estimate of the prescription duration. If
the provider was changed, the patient was still
followed unless the new provider was not cov-
ered by the database, in which case the patient
was censored. The duration of a prescription
was estimated as the median of the distribution
of the number of days between subsequent
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prescriptions (in patients with second up to
fifth consecutive prescriptions). Both refill per-
iod and prescription duration were estimated
separately for each BI or GLP-1 RA brand in each
country. A prescription was considered discon-
tinued if there was no prescription of the index
medication after the patient’s last prescription
plus 90 days. The persistence duration was cal-
culated from the index date until the discon-
tinuation date or until the cutoff date for the
study period.
HbA1c Outcomes
Monthly HbA1c distributions (mean ± stan-
dard deviation [SD]) from 12 months before to
24 months after the index date and the HbA1c
changes from baseline to each 6-month period
in 2 years were analyzed for each cohort in each
country. The cumulative percentages of patients
reaching HbA1c\ 7% during 24 months after
initiation were analyzed for the overall patient
cohorts for each injectable and country and for
subcohorts stratified by baseline HbA1c level,
number of OADs, and sulfonylurea versus non-
sulfonylurea use within the baseline period. The
probability of reaching first HbA1c\ 7% was
estimated within each quarter across 2 years.
The association between baseline characteristics
and the glycemic control outcome (defined as
reaching first HbA1c\7.0%) within 2 years
post-index date was analyzed for each
injectable cohort in either country.
Statistical Analysis
Descriptive statistics were used for baseline
characteristics. Categorical variables were sum-
marized as number and percentage; continuous
variables were summarized as mean ± SD and/
or median.
The 720-day post GLP-1 RA or BI initiation
period was divided into consecutive 180-day
periods. The mean change in HbA1c from
baseline to each 180-day period was calculated.
For each time period, data from patients with
both a baseline and a follow-up HbA1c within
the time period were included. If a patient had
more than one measurement within a window,
the value closest to the midpoint of that win-
dow was selected. The number of patients and
summary statistics for the change from baseline
(mean ± SD) are presented. Kaplan-Meier
curves were used to estimate the cumulative
incidence of reaching glycemic control after the
index date stratified by each subcohort. The
Kaplan-Meier curves included the time from the
first GLP-1 RA or BI prescription to the first
HbA1c measure\7% (outcome), end of GLP-1
RA or BI prescription (censoring event), or
switch in GLP-1 RA or BI medication to a new
non-GLP-1 RA or BI regimen (censoring event).
Log-rank tests were applied to compare Kaplan-
Meier curves between subcohorts. Within each
quarter in 2 years (total of 8 quarters, 4 per year)
after the index date, the probabilities of
achieving first HbA1c\7.0% in that quarter
were estimated using the percentages of
patients who reached glycemic control in the
respective quarter among those who remained
uncontrolled before that quarter.
A Cox proportional hazards model was
applied to identify possible associations
between baseline characteristics and the time to
reach first HbA1c\7.0% after initiation of GLP-
1 RA or BI, adjusted for potential confounding
factors due to the different covariates and dis-
tributions. However, given that the objective of
this study was not to compare the treatment
cohorts (but rather to describe the outcomes in
real-world clinical practice), no statistical
methodology such as propensity score match-
ing was applied. When data were missing for
patients or variables, a missing data category
was included. Variable selection in multivariate
models was performed using backward elimi-
nation. Starting with the full model, each vari-
able was dropped from the model, and a
likelihood ratio test performed comparing the
full model to each reduced model. The variable
with both the highest p value (thus the least
informative) and p[ 0.10 was dropped from the
model. The process was repeated until no vari-
ables met the criteria to be dropped from the
model. Age, gender, and baseline HbA1c were
included a priori in the model.
Subgroup analyses were performed with
similar statistical methodology. Statistical anal-
ysis was conducted for each of the four cohorts
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separately. Data from the four cohorts were not
merged for statistical testing across cohorts as
this was not a study objective, being not feasible
owing to the complexities of the two distinct
databases nor appropriate because of differences
in patient characteristics. Results for each
cohort are displayed side by side in tables and
figures to present the data efficiently. Any
comparisons described between GLP-1 RA and
BI, or between the US and the UK, are descrip-
tive only (no statistical testing was carried out
between the two countries).
RESULTS
Baseline Demographics and Patient
Characteristics
Overall, 97,823,311 patients from the US
Optum and 13,066,884 patients from the UK
CPRD databases had valid records as of June 30,
2018. After application of inclusion/exclusion
criteria, 20,836 and 60,598 patients from the US
Optum database were included in the GLP-1 RA
and BI cohorts, respectively. From the UK CPRD
database, 5508 and 5083 patients were included
in the GLP-1 RA and BI cohorts (Table S1).
Across all cohorts, patients initiating GLP-1
RA or BI had high HbA1c levels (mean
8.8–10.3%), mean age 55.9–64.8 years, long
duration of diabetes (mean 8.3 or 10.1 years in
the UK for GLP-1 RA or BI, respectively), and
various comorbidities and complications (in-
cluding dyslipidemia, obesity, hypertension,
and renal diseases and cardiovascular diseases).
The most frequent classes of OADs used during
the baseline period were metformin, sulfony-
lureas, dipeptidyl peptidase-4 inhibitors, and
thiazolidinediones (Table 1).
In both countries, GLP-1 RAs were prescribed
to patients at a younger age (and shorter dia-
betes duration in the UK) and higher body mass
index (BMI) compared with BI.
Medication Persistence
The persistence of GLP-1 RA or BI appeared to
be longer in the UK than in the US (Table S2).
Liraglutide and exenatide (daily/weekly) were
the most commonly prescribed GLP-1 RAs in
both databases. Glargine (Gla-300 and Gla-100)
and detemir were the most commonly pre-
scribed BIs in the US, and glargine (Gla-300 and
Gla-100) and neutral protamine Hagedorn were
the most commonly prescribed BIs in the UK.
The estimated persistence of antihyperglycemic
drugs that became available during the study
period may have been impacted by their shorter
duration of availability.
HbA1c Outcomes
In both databases, there was a trend of increas-
ing HbA1c values leading up to initiation of
GLP-1 RA or BI, followed by a significant
decrease in the 3–4 months following intensifi-
cation (Fig. 1); mean HbA1c remained
stable after this period. HbA1c change from
baseline within each 6-month period is sum-
marized in Table S3. A substantial reduction in
the number of patients with HbA1c records
occurred over time in the US database.
A higher HbA1c at baseline was associated
with a reduced chance of reaching HbA1c\ 7%
in all cohorts. The proportion of patients
reaching HbA1c\ 7% at 12 months was\ 25%
if baseline HbA1c was C 9% in both GLP-1 RA
and BI cohorts (Fig. 2a–d). The cumulative per-
centage of patients reaching HbA1c\ 7%
showed the greatest increase in the first
12 months, particularly in the first 6 months of
this time period (15%–40% of patients across
cohorts at 12 months) (Fig. 2e and f). Patients
who were on sulfonylureas at baseline were less
likely to reach HbA1c\7% than those who
were not, with the largest difference in GLP-1
RA-treated patients (Figure S2).
The quarterly probability of reaching
HbA1c\ 7% was highest in the second quarter
for all cohorts (probability * 0.1–0.3 across
cohorts; Fig. 3). A trend of decreasing probabil-
ity of reaching HbA1c\7% was observed
through Quarters 2 to 8.
Among all four cohorts, higher baseline
HbA1c level was consistently the strongest pre-
dictor of not achieving post-treatment
HbA1c\ 7% (Table 2). From the other factors,
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Table 1 Baseline characteristics
Patient characteristics US Optum UK CPRD
GLP-1 RA
cohort
(n = 20,836)
BI cohort
(n = 60,598)
GLP-1 RA cohort
(n = 5508)
BI cohort
(n = 5083)
Age at index [years], mean (SD) 55.9 (10.7) 60.7 (12.6) 57.5 (10.4) 64.8 (13.2)
BMI [kg/m2], mean (SD) 35.9 (7.6) 33.9 (8.0) 38.0 (6.8) 30.2 (6.0)
Unknown, n (%) 3689 (17.7) 213 (0.4) 647 (12.2) 1102 (21.7)
Duration of diabetes [years], mean
(SD)
NA NA 8.3 (5.0) 10.1 (6.5)
Unknown, n (%) 305 (0.1) 369 (0.1)
Baseline HbA1c
HbA1c %, mean (SD) 8.8 (1.4) 9.5 (1.9) 9.6 (1.5) 10.3 (1.9)
HbA1c mmol/mol, mean (SD) 73 (15.3) 80 (20.8) 81 (16.4) 89 (20.8)
7 to\ 8%, n (%) 6844 (32.8) 14,323 (23.6) 696 (12.6) 401 (7.9)
C 8 to\ 9%, n (%) 6411 (30.8) 14,025 (23.1) 1467 (26.6) 997 (19.6)
C 9%, n (%) 7581 (36.4) 32,250 (53.2) 3345 (60.7) 3685 (72.5)
Common comorbidities or complications, n (%)
Dyslipidemia 17,987 (86.3) 50,350 (83.1) 4909 (89.1) 4445 (87.5)
Obesity 18,537 (89.0) 46,281 (76.4) 5313 (96.5) 3273 (64.4)
Hypertension 17,020 (81.7) 50,044 (82.6) 3677 (66.8) 3322 (65.4)
Chronic kidney disease 1667 (8.0) 9255 (15.3) 715 (13.0) 1418 (27.9)
Arrhythmia 2218 (10.7) 11,499 (19.0) 268 (4.9%) 520 (10.2)
Stroke or transient ischemic
attack
593 (2.9) 3905 (6.4) 195 (3.5) 357 (7.0)
Congestive heart failure 951 (4.6) 7065 (11.7) 133 (2.4) 299 (5.9)
Peripheral vascular disease 231 (1.1) 1512 (2.5) 136 (2.5) 224 (4.4)
Myocardial infarction 1350 (6.5) 7569 (12.5) 189 (3.4) 282 (5.6)
Unique OAD classes used within 180 days prior (grouped), n (%)
1 8586 (41.2) 26,466 (43.7) 864 (15.7) 1080 (21.3)
2 4587 (22.0) 23,845 (39.4) 2161 (39.2) 1899 (37.4)
C 3 7663 (36.8) 10,287 (17.0) 2483 (45.1) 2104 (41.4)
OAD use by class in baseline, n (%)
Metformin 16,698 (80.1) 44,840 (74.0) 5099 (92.6) 4125 (81.2)
Sulfonylureas 10,856 (52.1) 35,517 (58.6) 3652 (66.3) 4044 (79.6)
Dipeptidyl peptidase-4 inhibitors 6737 (32.3) 16,563 (27.3) 2684 (48.7) 2182 (42.9)
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the use of[1 OAD was a predictor of not
achieving HbA1c in both US groups and in the
UK group treated by GLP-1 RA. Baseline treat-
ment with sulfonylurea was a predictor of
nonachievement of the HbA1c goal in both US
cohorts; baseline treatment with insulin was a
predictor of nonachievement of the HbA1c goal
in UK patients treated with GLP-1 RA.
DISCUSSION
This retrospective observational study evaluated
the effectiveness of initiating therapy with
either a GLP-1 RA or BI in adults with T2D
inadequately controlled on OADs in US and UK
real-world clinical practices. The likelihood of
achieving control with a single injectable medi-
cation added to oral therapy at an HbA1c[ 9%
was only 25%. In addition, there was a dimin-
ishing probability of reaching glycemic control
if the target HbA1c was not achieved within the
first 6 months on either regimen.
Although there were some differences
between the US and UK populations in this
study that made a direct comparison between
countries inappropriate, they did share some
common characteristics. Patients had a mean
age of[55 years and a long duration of T2D
([8 years; only UK data available), and most
had comorbidities. Patients also had a high
mean BMI ([ 30 kg/m2) and a high mean
HbA1c (US 8.8% and 9.5%, and in the UK 9.6%
and 10.3%, for patients initiating GLP-1 RAs or
BIs, respectively) despite most being treated
with C 2 OADs. Given the high mean HbA1c
values observed, additional oral agents, such as
sodium-glucose cotransporter 2 inhibitors
(SGLT2i’s), which have been demonstrated to
reduce HbA1c by between -0.21 and -0.78%
[17], would be unlikely to achieve glycemic
goals of\ 7% within the patient populations
included in this study. GLP-1 RA use for those
already on a SGLT2i has been shown to be
effective in helping individuals reach thera-
peutic targets [18, 19]. These observations may
reflect that in clinical practice in both countries,
injectable therapies are reserved for patients
with relatively advanced disease.
Additionally, injectable therapy in the UK is
often provided via secondary care (e.g., diabetes
specialists in hospital services); referrals from
primary care to secondary care may cause delay
in initiating injectable therapy.
In both countries, patients initiating GLP-1
RAs were younger and more obese than those
initiating BI. In the UK, these patients had a
mean BMI of 38 kg/m2 at initiation of GLP-1
RAs versus 30 kg/m2 at BI initiation. This may
result from the UK guidelines that recommend
GLP-1 RA therapy for T2D individuals with a
BMI C 35 kg/m2, and in those with a
BMI\35 kg/m2, where insulin therapy would
have significant occupational implications or
Table 1 continued
Patient characteristics US Optum UK CPRD
GLP-1
RAcohort
(n = 20,836)
BI cohort
(n = 60,598)
GLP-1 RA cohort
(n = 5508)
BI cohort
(n = 5083)
Thiazolidinediones 2522 (12.1) 6011 (9.9) 1176 (21.4) 802 (15.8)
Sodium-glucose cotransporter-2
inhibitors
2145 (10.3) 2101 (3.5) 133 (2.4) 109 (2.1)
Meglitinide 248 (1.2) 879 (1.5) 54 (1.0) 55 (1.1)
Alpha-glucosidase inhibitors 85 (0.4) 338 (0.6) 28 (0.5) 30 (0.6)
BI basal insulin, CPRD Clinical Practice Research Datalink, GLP-1 RA glucagon-like peptide-1 receptor agonist, HbA1c
glycated hemoglobin, NA not available, OAD oral antihyperglycemic drug, UK United Kingdom, US United States
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weight loss would benefit other significant
obesity-related comorbidities [3].
A backward elimination multivariate Cox
proportional hazard model was used to identify
possible associations between baseline charac-
teristics and glycemic control in each of the four
cohorts. Baseline characteristics found to be
associated with reduced likelihood of achieving
glycemic control included a higher HbA1c level,
longer duration of T2D (UK cohorts), increased
number of OADs, and use of sulfonylureas (US
Fig. 1 Monthly HbA1c distributions from 12 months before to 24 months after initiation of GLP-1 RA or BI in the US
(a, b) and UK (c, d). BI basal insulin, GLP-1 RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin
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cohorts), which may all be related to reduced b-
cell function.
Of all the baseline characteristics assessed,
baseline HbA1c level was the strongest predictor
of the likelihood of glycemic control achieve-
ment. In the 12 months after initiation of either
injectable in both countries, patients with a
baseline HbA1c of 7–8% had a 40–60% proba-
bility of obtaining an HbA1c\7%; those with
baseline HbA1c of 8–9% had less chance
(25–40%), and those with baseline HbA1c C 9%
had the lowest probability (\ 25% across all
cohorts). These results suggest clinicians should
consider intensification of therapy with a GLP-1
RA or BI before reaching an HbA1c value of
C 9% to maximize the likelihood of achieving
the target HbA1c. If an HbA1c\7% is not
achieved 6–12 months after initiating a single
injectable, further intensification should be
considered, as the probability of achieving
control with unchanged therapy is low. For
those with HbA1c C 9.0%, prior to first inject-
able, clinicians should consider a combination
of GLP-1 RA and insulin at initiation.
Cumulative incident curves for the propor-
tions of patients reaching HbA1c\ 7%
demonstrated a sharp increase in the first
6–12 months with little increase thereafter.
Additionally, quarterly probabilities showed
that the best chance of a person achieving an
HbA1c\ 7% was shortly after initiation of
injectables and diminished quickly thereafter,
remaining\10% in the second year. Blonde
et al. revealed similar findings in adults with
T2D initiating BI based on data from the US IBM
Explorys database [20]. Together, these results
suggest that the chance of achieving glycemic
control is much lower after the first year of
Fig. 2 Proportion of all patients achieving HbA1c\ 7%
by baseline HbA1c (C 7% to\ 8% vs. C 8% to\ 9%
vs. C 9%) for patients initiated on GLP-1 RAs in the US
(a) and UK (b), and for patients initiated on BI in the US
(c) and UK (d), and for the overall population in the US
and UK initiated on GLP-1 RAs (e) and those initiated on
BI (f). BI basal insulin, GLP-1 RA glucagon-like peptide-1
receptor agonist, HbA1c glycated hemoglobin, UK United
Kingdom, US United States
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treatment and that if, despite adequate dosing
of GLP-1 RA or BI, people have not reached their
target HbA1c after 6–12 months, further inten-
sification with additional medications and/or
switching to more potent therapy should be
considered.
The datasets used in the present study are
considered well representative of the patient
populations in both countries. However, there
are a number of limitations including bias
inherent to retrospective analyses of EMR and
claims data [21]. Retrospective real-world evi-
dence studies do not have initial randomization
to fully control for known and unknown con-
founders. Moreover, patient monitoring and
follow-up are not consistent [21]. In both data-
sets, data were collected from clinical practice
and were not specifically designed for research
purposes. As a result, often data that would be
useful for analysis may be missing, erroneous, or
misclassified [22]. Moreover, dosing
information of BI was not available, and indi-
vidual glycemic control goals were not avail-
able. Thus, it is not possible to tell for all
injectables if they were up-titrated to their
maximum effective dose and how well people
adhered to treatment. The American Diabetes
Association Standards of Care state that a rea-
sonable HbA1c goal for many nonpregnant
adults is\7% [1]; however, local guidelines,
factors such as age or comorbidities, or patient/
HCP choice may limit the number of people
striving for this target.
Additionally, there is clinical practice infor-
mation that EMR and claims databases do not
usually include, such as reasons for therapy
choice, or the events that may have resulted in
the sharp rise in HbA1c 3–6 months before
injectable therapy was initiated (e.g., intercur-
rent illness, decreased adherence because of
medication side effects or cost issues). Lastly,
the study period may have limited the inclusion
Fig. 3 Probability of reaching first HbA1c\ 7% within
each quarter post-initiation of either injectable (a, c: US; b,
d: UK). GLP-1 RA glucagon-like peptide-1 receptor
agonist, HbA1c glycated hemoglobin, Q quarter, UK
United Kingdom, US United States
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Table 2 Hazard ratios by baseline variable for the nonachievement of HbA1c\ 7.0% post-initiation of GLP-1RA or BIa
Variable Comparator Reference GLP-1 RA BI
HR (95% CI) p value HR (95% CI) p value
US cohorts
Age (years) [ 65 B 65 1.01 (0.94–1.09) 0.770 1.04 (1.00–1.08) 0.073
Sex Male Female 0.92 (0.88–0.97) \ 0.001 1.12 (1.08–1.15) \ 0.001
Race Asian Black 0.73 (0.56–0.97) 0.028 0.82 (0.72–0.94) 0.004
White 1.18 (1.08–1.28) \ 0.001 1.11 (1.05–1.16) \ 0.001
Unknown 1.07 (0.93–1.23) 0.326 0.9 (0.81–0.99) 0.024
Ethnicity Not Hispanic Hispanic Not selected 1.14 (1.06–1.23) \ 0.001
Unknown 0.95 (0.85–1.06) 0.386
Region Northeast Midwest 1.05 (0.96–1.16) 0.289 0.89 (0.83–0.96) 0.001
South 1.07 (1.01–1.13) 0.014 1.04 (1.00–1.07) 0.057
West 1.23 (1.12–1.35) \ 0.001 1.21 (1.13–1.29) \ 0.001
Other/unknown 1.13 (0.98–1.29) 0.093 0.93 (0.84–1.02) 0.114
Insurance Medicaid Medicare 0.83 (0.72–0.96) 0.012 0.90 (0.84–0.96) 0.003
Commercial 1.00 (0.94–1.08) 0.908 0.96 (0.92–1.00) 0.050
Uninsured 0.81 (0.64–1.02) 0.072 0.79 (0.71–0.88) \ 0.001
Other/unknown 0.94 (0.85–1.04) 0.247 0.98 (0.93–1.04) 0.460
HbA1c (%) 8 to\ 9 7 to\ 8 0.59 (0.56–0.63) \ 0.001 0.60 (0.58–0.63) \ 0.001
C 9 0.38 (0.36–0.41) \ 0.001 0.49 (0.47–0.51) \ 0.001
Dyslipidemia Yes No 1.07 (0.99–1.14) 0.075 Not selected
Arrhythmia Yes No 1.08 (1.00–1.16) 0.047 1.11 (1.06–1.15) \ 0.001
OADs used at baseline (n) 2 1 0.90 (0.85–0.95) \ 0.001 1.16 (1.11–1.21) \ 0.001
C 3 0.80 (0.74–0.86) \ 0.001 1.07 (1.03–1.11) \ 0.001
CKD Yes No 0.97 (0.94–1.01) 0.145
Cardiovascular eventsb Yes No 0.91 (0.87–0.96) \ 0.001
SU use at baseline SU No SU 0.83 (0.78–0.87) \ 0.001 0.83 (0.80–0.86) \ 0.001
UK cohorts
Age (years) [ 65 B 65 1.26 (1.10–1.44) \ 0.001 1.12 (0.97–1.29) 0.136
Sex Male Female 0.99 (0.88–1.10) 0.790 1.10 (0.97–1.26) 0.147
HbA1c (%) 8 to\ 9 7 to\ 8 0.60 (0.52–0.69) \ 0.001 0.76 (0.61–0.96) 0.023
C 9 0.27 (0.24–0.32) \ 0.001 0.47 (0.39–0.58) \ 0.001
Dyslipidemia Yes No 0.85 (0.72–1.00) 0.053 0.71 (0.59–0.86) \ 0.001
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of data about more recently marketed GLP-1
RAs or BIs as well as data with the addition of
either drug class on top of the SGLT2 inhibitors
that have become more popular in the past
several years.
This retrospective, observational, longitudi-
nal cohort study using two large EMR and
claims databases revealed the effectiveness in
real-world practice of initiating GLP-1 RA or BI
medications in the US and UK between 2010
and 2016, with a 2-year follow-up. These med-
ications were mostly initiated in people with
T2D with long disease duration, various com-
plications/comorbidities, high BMI, and a high
HbA1c despite ongoing OAD treatment. Our
results suggest that clinicians should consider
earlier intensification of therapy with a GLP-1
RA or BI before reaching an HbA1c value of
C 9% to maximize the likelihood of achieving
target HbA1c. Regimens with greater antihy-
perglycemic efficacy including combination
injectable therapy may be warranted for those
people with HbA1c C 9% despite taking multi-
ple OADs, since in the present study the likeli-
hood of achieving control with a single
injectable medication added to oral therapy
once HbA1c is[9% was only about 25%, much
less than the likelihood of achieving control
when injectable therapy is started at a lower
HbA1c. In addition, if glycemic control has not
been achieved within the first 6 months of
treatment with either regimen, there is a
diminishing probability that control will be
achieved without further treatment intensifica-
tion, which should be considered.
Table 2 continued
Variable Comparator Reference GLP-1 RA BI
HR (95% CI) p value HR (95% CI) p value
OADs used at baseline (n) 2 1 0.68 (0.58–0.80) \ 0.001 1.01 (0.84–1.22) 0.907
C 3 0.43 (0.36–0.53) \ 0.001 0.76 (0.62–0.94) 0.010
SU use at baseline SU No SU 0.97 (0.84–1.11) 0.646 0.85 (0.71–1.03) 0.098
Insulin use at baseline
(other than BI)
Insulin No insulin 0.50 (0.36–0.67) \ 0.001 Not selected
Diabetes duration (years) 5 to\ 10 0 to 5 0.81 (0.70–0.93) 0.003 0.62 (0.51–0.74) \ 0.001
10 to\ 15 0.79 (0.66–0.93) 0.005 0.63 (0.52–0.77) \ 0.001
15 to\ 20 0.69 (0.53–0.91) 0.008 0.55 (0.43–0.71) \ 0.001
C 20 0.70 (0.45–1.09) 0.111 0.62 (0.47–0.83) 0.001
Unknown 0.91 (0.71–1.17) 0.468 0.75 (0.57–0.98) 0.033
The event in the Cox regression models was defined as ‘‘achieving first HbA1c\ 7.0% post initiation of GLP-1 RA or BI,’’
so the statistical term ‘‘hazard ratio’’ should be interpreted as ‘‘benefit ratio’’ clinically
BI basal insulin, CKD chronic kidney disease, GLP-1 RA glucagon-like peptide-1 receptor agonist, HbA1c glycated
hemoglobin, HR hazard ratio, OAD oral antidiabetic drug, SU sulfonylurea, UK United Kingdom, US United States
a Multivariant Cox regression model selected using backward elimination, where each variable was sequentially dropped
from the model and the fit was compared with the original model using the likelihood ratio test. Of the variables with a
nonsignificant p value (p[ 0.1), the variable with the highest p value was removed. This was repeated until no variables
could be dropped from the model (i.e., all p\ 0.1)
b Including myocardial infarction, stroke/transient ischemic event, peripheral vascular disease, congestive heart failure, and/
or coronary artery bypass grafting
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